SCHEMBL4908103

SCHEMBL4908103

CCOC(=O)c1cccc2c1ncn2CCC(C)(C)NCC(O)c1ccccc1NS(=O)(=O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.47
KMT2A Q03164 3/20 0.47
LMNA P02545 4/20 0.44
KDM4E B2RXH2 4/20 0.44
HTT P42858 2/20 0.44
GAA P10253 2/20 0.44
NPC1 O15118 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
ALDH1A1 P00352 7/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
HPGD P15428 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
TP53 P04637 1/20 0.40
MCL1 Q07820 1/20 0.40
MAPT P10636 2/20 0.40
THRB P10828 2/20 0.36
BLM P54132 2/20 0.36
PLEC Q15149 1/20 0.36
ADRB2 P07550 1/20 0.36
ADRB1 P08588 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4916195 0.99 TSHR (0.47) TSHRKMT2ALMNAKDM4EHTT
SCHEMBL4908096 0.87 ADRB3 (0.42) TSHRKMT2ALMNAKDM4EHTT
Hydrochloric Acid SCHEMBL4916184 0.86 ADRB3 (0.41) TSHRKMT2ALMNAKDM4EHTT
SCHEMBL4892969 0.85 KMT2A (0.41) TSHRKMT2ALMNAKDM4EHTT
SCHEMBL4913376 0.85 TSHR (0.41) TSHRKMT2ALMNAKDM4EHTT
SCHEMBL2199552 0.85 TSHR (0.41) TSHRKMT2ALMNAKDM4EHTT
SCHEMBL4889584 0.84 KMT2A (0.40) TSHRKMT2ALMNAKDM4EHTT
SCHEMBL4894089 0.84 TSHR (0.40) TSHRKMT2ALMNAKDM4EHTT
SCHEMBL4914688 0.83 YTHDC1 (0.36) KMT2ALMNAKDM4ETDP1ALDH1A1
SCHEMBL4893741 0.82 KMT2A (0.41) TSHRKMT2ALMNAKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080103138-A1 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-05-01 US disclosed
US-20070112033-A1 N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103138-A1 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions ADRB1, ADRB3, ADRB2 TSHR 466/4885KMT2A 4734/4885LMNA 880/4885
US-20070112033-A1 N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance ADRB3, ADRB1, ADRA1B TSHR 85/4885KMT2A 4585/4885LMNA 1223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.